CLAIMS

1. A dosage form comprising:

(a) a capsule shell; and

(b) at least one tablet within the capsule shell, the at least one tablet containing 5-aminosalicylic acid or a salt thereof as an active ingredient and having an enteric coat.

2. A kit comprising:

a dosage form according to claim 1; and

a predetermined amount of desiccant.

3. Use of the dosage form according to claim 1 in the manufacture of a medicament useful for the treatment of an inflammatory condition of the gastrointestinal tract.

4. A dosage form comprising:

(a) a capsule shell; and

(b) at least one tablet within the capsule shell, the at least one tablet containing 5-aminosalicylic acid or a salt thereof as an active ingredient and having an enteric coat,

wherein the capsule shell has less than about 10% by weight moisture content at a relative humidity of 60% and a temperature of 25°C.

5. The dosage form according to claim 4, wherein the dosage form is stable.

6. The dosage form according to claim 5, wherein no more than 0.15% w/w 5-[2-formyl-5-(hydroxymethyl-1H-pyrrol-1-yl]-2-hydroxybenzoic acid accumulates upon storage of the dosage form at a relative humidity of 60% and a temperature of 25°C.

25. The dosage form according to claim 4, wherein the at least one tablet is greater than 5mm in diameter.

26. A kit comprising:

a dosage form according to claim 4; and

a predetermined amount of desiccant.

27. Use of the dosage form according to claim 4 in the manufacture of a medicament useful for the treatment of an inflammatory condition of the gastrointestinal tract.

28. A method of improving the handling properties of a 5-aminosalicylic acid dosage form comprising the steps of:

providing at least one tablet containing 5-aminosalicylic acid or a salt thereof as an active ingredient and having an enteric coat; and

encapsulating the at least one tablet in a capsule shell.

29. A method of improving the stability of a 5-aminosalicylic acid dosage form comprising the steps of:

providing at least one tablet containing 5-aminosalicylic acid or a salt thereof as an active ingredient and having an enteric coat; and

encapsulating the at least one tablet in a capsule shell,

wherein the capsule shell has less than about 10% by weight moisture content at a relative humidity of 60% and a temperature of 25°C.

30. A method of modifying the dissolution profile of a dosage form upon storage comprising the step of:

providing a dosage form according to claim 4 in a kit comprising the dosage form and a predetermined amount of desiccant.